Literature DB >> 30218311

Essentials in Candida bloodstream infection.

Sibylle C Mellinghoff1,2, O A Cornely3,4,5,6, N Jung4.   

Abstract

AIMS: Due to the increase of severely immunocompromised patients, of invasive procedures including central intravascular catheters, and of the use of broad-spectrum antibiotics, the incidence of Candida bloodstream infections has risen intensely in the last decades. Candida bloodstream infection is a serious disease with high mortality. Optimized diagnostic and therapeutic management can improve outcome. Thus, the aim of our mini-review is to highlight important and often missed opportunities in the management of Candida bloodstream infection.
METHODS: We searched the published literature and describe the essentials in the management of Candida bloodstream infection.
RESULTS: Four essentials were identified: (1) isolation of Candida spp. from a blood culture should always be considered relevant and requires treatment. Daily blood cultures should be drawn to determine cessation of candidemia. (2) Central venous catheter (CVC) and/or other indwelling devices should be removed. (3) Echinocandins are the first choice. Antifungal treatment should be continued for at least 14 days after cessation of fungemia. Susceptibility testing should be performed to identify resistance and to facilitate transition to oral treatment. (4) In persistent candidemia, echocardiography is an important investigation; ophthalmoscopy should be considered.
CONCLUSION: Further efforts should be undertaken to increase the adherence to the essentials in the management of Candia bloodstream infection.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30218311     DOI: 10.1007/s15010-018-1218-1

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  27 in total

Review 1.  Fungal endocarditis.

Authors:  Daniela Tacke; Philipp Koehler; Oliver A Cornely
Journal:  Curr Opin Infect Dis       Date:  2013-12       Impact factor: 4.915

2.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

Authors:  O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

3.  Analyzing candidemia guideline adherence identifies opportunities for antifungal stewardship.

Authors:  Sibylle C Mellinghoff; Pia Hartmann; Florian B Cornely; Laura Knauth; Felix Köhler; Philipp Köhler; Carolin Krause; Christine Kronenberg; Sarah-Leonie Kranz; Vidya Menon; Hannah Müller; Jan-Hendrik Naendrup; Stefan Pützfeld; Anna Ronge; Jule Rutz; Danila Seidel; Hilmar Wisplinghoff; Oliver A Cornely
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-13       Impact factor: 3.267

4.  Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes.

Authors:  Shellee A Grim; Karen Berger; Christine Teng; Sandeep Gupta; Jennifer E Layden; William M Janda; Nina M Clark
Journal:  J Antimicrob Chemother       Date:  2011-12-18       Impact factor: 5.790

5.  Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia.

Authors:  Maiken Cavling Arendrup; Sofia Sulim; Anette Holm; Lene Nielsen; Susanne Dam Nielsen; Jenny Dahl Knudsen; Niels Erik Drenck; Jens Jørgen Christensen; Helle Krogh Johansen
Journal:  J Clin Microbiol       Date:  2011-06-29       Impact factor: 5.948

6.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

7.  Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.

Authors:  Ernst-Rüdiger Kuse; Ploenchan Chetchotisakd; Clovis Arns da Cunha; Markus Ruhnke; Carlos Barrios; Digumarti Raghunadharao; Jagdev Singh Sekhon; Antonio Freire; Venkatasubramanian Ramasubramanian; Ignace Demeyer; Marcio Nucci; Amorn Leelarasamee; Frédérique Jacobs; Johan Decruyenaere; Didier Pittet; Andrew J Ullmann; Luis Ostrosky-Zeichner; Olivier Lortholary; Sonja Koblinger; Heike Diekmann-Berndt; Oliver A Cornely
Journal:  Lancet       Date:  2007-05-05       Impact factor: 79.321

8.  Anidulafungin versus fluconazole for invasive candidiasis.

Authors:  Annette C Reboli; Coleman Rotstein; Peter G Pappas; Stanley W Chapman; Daniel H Kett; Deepali Kumar; Robert Betts; Michele Wible; Beth P Goldstein; Jennifer Schranz; David S Krause; Thomas J Walsh
Journal:  N Engl J Med       Date:  2007-06-14       Impact factor: 91.245

9.  Abdominal candidiasis is a hidden reservoir of echinocandin resistance.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

10.  Factors related to outcome of bloodstream infections due to Candida parapsilosis complex.

Authors:  Francesco Barchiesi; Elena Orsetti; Patrizia Osimani; Carlo Catassi; Fabio Santelli; Esther Manso
Journal:  BMC Infect Dis       Date:  2016-08-09       Impact factor: 3.090

View more
  4 in total

1.  Comparison of Two Commercial Colorimetric Broth Microdilution Tests for Candida Susceptibility Testing: Sensititre YeastOne versus MICRONAUT-AM.

Authors:  Sophie Philips; Frederik Van Hoecke; Emmanuel De Laere; Steven Vervaeke; Roos De Smedt; Jerina Boelens; Deborah De Geyter; Denis Piérard; Katrien Lagrou
Journal:  J Fungi (Basel)       Date:  2021-05-01

Review 2.  Malassezia spp. Yeasts of Emerging Concern in Fungemia.

Authors:  Wafa Rhimi; Bart Theelen; Teun Boekhout; Domenico Otranto; Claudia Cafarchia
Journal:  Front Cell Infect Microbiol       Date:  2020-07-28       Impact factor: 5.293

3.  A seven-year surveillance study of the epidemiology, antifungal susceptibility, risk factors and mortality of candidaemia among paediatric and adult inpatients in a tertiary teaching hospital in China.

Authors:  Zhangrui Zeng; Yinhuan Ding; Gang Tian; Kui Yang; Jian Deng; Guangrong Li; Jinbo Liu
Journal:  Antimicrob Resist Infect Control       Date:  2020-08-14       Impact factor: 4.887

4.  Combined Use of Presepsin and (1,3)-β-D-glucan as Biomarkers for Diagnosing Candida Sepsis and Monitoring the Effectiveness of Treatment in Critically Ill Patients.

Authors:  Radim Dobiáš; Marcela Káňová; Naděžda Petejová; Štefan Kis Pisti; Robert Bocek; Eva Krejčí; Helena Stružková; Michaela Cachová; Hana Tomášková; Petr Hamal; Vladimír Havlíček; Milan Raška
Journal:  J Fungi (Basel)       Date:  2022-03-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.